image
Healthcare - Biotechnology - NASDAQ - US
$ 48.915
-1.5 %
$ 2.04 B
Market Cap
-15.8
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TARS stock under the worst case scenario is HIDDEN Compared to the current market price of 48.9 USD, Tarsus Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TARS stock under the base case scenario is HIDDEN Compared to the current market price of 48.9 USD, Tarsus Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TARS stock under the best case scenario is HIDDEN Compared to the current market price of 48.9 USD, Tarsus Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TARS

image
$58.0$58.0$56.0$56.0$54.0$54.0$52.0$52.0$50.0$50.0$48.0$48.0$46.0$46.0$44.0$44.0$42.0$42.0$40.0$40.0$38.0$38.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
183 M REVENUE
948.62%
-121 M OPERATING INCOME
15.78%
-116 M NET INCOME
14.97%
-83 M OPERATING CASH FLOW
29.33%
-199 M INVESTING CASH FLOW
-141.67%
155 M FINANCING CASH FLOW
18.81%
66.4 M REVENUE
38.01%
-24.4 M OPERATING INCOME
2.94%
-23.1 M NET INCOME
1.31%
-22.2 M OPERATING CASH FLOW
-156.38%
-59.6 M INVESTING CASH FLOW
-1904.54%
2.93 M FINANCING CASH FLOW
358.06%
Balance Sheet Tarsus Pharmaceuticals, Inc.
image
Current Assets 357 M
Cash & Short-Term Investments 291 M
Receivables 48.1 M
Other Current Assets 17.3 M
Non-Current Assets 20.3 M
Long-Term Investments 3 M
PP&E 2.87 M
Other Non-Current Assets 14.4 M
77.29 %12.75 %4.58 %3.83 %Total Assets$377.0m
Current Liabilities 80.6 M
Accounts Payable 27.7 M
Short-Term Debt 608 K
Other Current Liabilities 52.3 M
Non-Current Liabilities 71.8 M
Long-Term Debt 71.8 M
Other Non-Current Liabilities 0
18.19 %34.28 %47.12 %Total Liabilities$152.5m
EFFICIENCY
Earnings Waterfall Tarsus Pharmaceuticals, Inc.
image
Revenue 183 M
Cost Of Revenue 12.8 M
Gross Profit 170 M
Operating Expenses 291 M
Operating Income -121 M
Other Expenses -5.02 M
Net Income -116 M
200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)183m(13m)170m(291m)(121m)5m(116m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
92.99% GROSS MARGIN
92.99%
-65.90% OPERATING MARGIN
-65.90%
-63.16% NET MARGIN
-63.16%
-51.46% ROE
-51.46%
-30.65% ROA
-30.65%
-40.60% ROIC
-40.60%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Tarsus Pharmaceuticals, Inc.
image
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)20192019202020202021202120222022202320232024202420252025
Net Income -116 M
Depreciation & Amortization 1.22 M
Capital Expenditures -1.57 M
Stock-Based Compensation 27.8 M
Change in Working Capital 3.84 M
Others -4.67 M
Free Cash Flow -84.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Tarsus Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for TARS of $63.2 , with forecasts ranging from a low of $58 to a high of $72 .
TARS Lowest Price Target Wall Street Target
58 USD 18.57%
TARS Average Price Target Wall Street Target
63.2 USD 29.20%
TARS Highest Price Target Wall Street Target
72 USD 47.19%
Price
Max Price Target
Min Price Target
Average Price Target
8080707060605050404030302020Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 20
6. Ownership
Insider Ownership Tarsus Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
3.3 M USD 6
3-6 MONTHS
0 USD 0
6-9 MONTHS
913 K USD 1
9-12 MONTHS
287 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the impact of XDEMVY® (lotilaner ophthalmic solution) 0.25% in addressing objective measures of disease at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting, taking place April 25-28, 2025, in Los Angeles, Calif. globenewswire.com - 1 week ago
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public offering price of $44.50 per share. In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 421,348 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tarsus, are expected to be approximately $125.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on March 14, 2025, subject to the satisfaction of customary closing conditions. globenewswire.com - 1 month ago
Tarsus Announces Proposed $100.0 Million Public Offering IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock. Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering. All shares in the proposed offering are to be sold by Tarsus. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. globenewswire.com - 1 month ago
Tarsus Pharma: Strong Execution In Xdemvy Commercialization Tarsus Pharmaceuticals' Xdemvy, the first approved treatment for Demodex blepharitis, generated $180M in 2024 sales, with significant growth potential in a large addressable market. Analysts project Tarsus' revenue to reach $352M in 2025, driven by expanding sales, Medicare/Medicaid reimbursement, and increasing consumer awareness. Tarsus' pipeline includes promising candidates TP-04 for Ocular Rosacea and TP-05 for Lyme disease, enhancing long-term growth prospects. seekingalpha.com - 1 month ago
Tarsus to Participate in Upcoming Investor Conference IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11th, at 8:00 a.m. / 11:00 a.m. ET. globenewswire.com - 1 month ago
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants David Nakasone - Head of IR Bobby Azamian - CEO and Chairman Aziz Mottiwala - CCO Seshadri Neervannan - COO Jeff Farrow - CFO and CSO Conference Call Participants Francois Brisebois - Oppenheimer Corey Jubinville - Life Sci Capital Jason Gerberry - Bank of America Oren Livnat - HC Wainright Eddie Hickman - Guggenheim Securities Andrea Newkirk - Goldman Sachs Lachlan Hanbury-Brown - William Blair Operator Good morning, and welcome to Tarsus Year End 2024 Financial Results Conference Call. As a reminder, this call is being recorded. seekingalpha.com - 2 months ago
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $1.31 per share a year ago. zacks.com - 2 months ago
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter and full-year 2024 financial results and provide a corporate update. globenewswire.com - 2 months ago
Tarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in fireside chats at two upcoming investor conferences: globenewswire.com - 3 months ago
Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com - 3 months ago
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for 2H 2025 globenewswire.com - 3 months ago
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025. zacks.com - 4 months ago
8. Profile Summary

Tarsus Pharmaceuticals, Inc. TARS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 2.04 B
Dividend Yield 0.00%
Description Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Contact 15440 Laguna Canyon Road, Irvine, CA, 92618 https://www.tarsusrx.com
IPO Date Oct. 16, 2020
Employees 323
Officers Dr. Seshadri Neervannan Ph.D. Chief Operating Officer Dr. Elizabeth Yeu M.D. Chief Medical Officer Mr. David Nakasone Head of Investor Relations Ms. Dianne C. Whitfield M.S.W. Chief Human Resources Officer Mr. Aziz Mottiwala M.B.A. Chief Commercial Officer Mr. Matthew Rossen M.B.A. Vice President of Marketing Dr. Bobak R. Azamian M.D. Co-Founder, President, Chief Executive Officer & Chairman Dr. Bryan Wahl J.D., M.D. General Counsel & Corporate Secretary Ms. Adrienne Kemp Senior Director of Corporate Communications Mr. Scott Youmans Vice President of Sales